Growth signals Revenue resilience with a recent quarterly revenue of 8.9M and ongoing product launches indicates potential for additional clinical and commercialization partnerships in oncology delivery systems.

Leadership changes Upcoming leadership transitions in clinical operations and medical leadership present an opportunity to engage on strategic programs, collaborations, or advisory roles as the new executives refine execution.

Delivery platform Recent launch of TriNav LV Infusion System and TriGuide Guiding Catheter highlights a focus on delivery optimization, suggesting cross-sell potential to expand into combined device and biologic/immunotherapy programs.

Market focus Specialization in liver and pancreatic tumor treatments positions the company to partner with hospitals and centers of excellence treating GI malignancies, enabling targeted outreach for access, trial collaborations, and payer strategies.

Strategic gaps Board changes and leadership turnover indicate a window for engaging in strategic partnerships, CRO collaborations, and advisory opportunities to support clinical development and manufacturing scaling.